This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Close

AboutAboutAbout APEXXNARMechanism of actionClinical programmeClinical programmeAPEXXNAR clinical study overviewAPEXXNAR adverse drug reactionsAdministration
An expanded level of protection1,2APEXXNAR® is a 20-valent pneumococcal conjugate vaccine for adults that helps protect against the 20 Streptococcus pneumoniae serotypes included in the vaccine.1

APEXXNAR is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.1 

Apexxnar may be administered concomitantly with seasonal influenza vaccine (QIV; surface antigen, inactivated, adjuvanted) and COVID-19 mRNA vaccine (nucleoside modified).1

TitleAPEXXNAR adds 7 serotypes to Prevenar 13® (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]).1,2 Help protect your adult patients from pneumococcal disease1

Manifestations of pneumococcal disease include:3

 Pneumococcal pneumonia Bacteraemia Meningitis​​​​​​​

▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Refer to section 4.8 for how to report adverse reactions.

TitleRegardless of whether your patients have previously received a pneumococcal vaccination, consider if APEXXNAR could help provide additional protection1References:APEXXNAR® Summary of Product Characteristics.Prevenar 13® Summary of Product Characteristics.Health Service Executive (HSE). Pneumococcal Disease: Adult Vaccines. Available at: https://www.hse.ie/eng/health/immunisation/pubinfo/adult/pneumo/ Last Accessed: August 2022ClinicalTrials.gov. Trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults. Available at: https://clinicaltrials.gov/ct2/show/NCT03760146 Last Accessed: August 2022.ClinicalTrials.gov. Trial to evaluate the safety and immunogenicity of 3 lots of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults. Available at: https://clinicaltrials.gov/ct2/show/NCT03828617 Last Accessed: August 2022.ClinicalTrials.gov. Trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal vaccine in adults 65 years of age or older with prior pneumococcal vaccination. Available at: https://clinicaltrials.gov/ct2/show/NCT03835975 Last Accessed: August 2022.Froes F, Roche N, Blasi F. Pneumococcal vaccination and chronic respiratory diseases. Int J Chron Obstruct Pulmon Dis. 2017;12:3457-3468. About Study overview

APEXXNAR® was evaluated for safety and immunogenicity across a diverse patient population.1,4-6

 Review the data Loading How does APEXXNAR work?

Conjugate vaccines like APEXXNAR are designed to deliver long-lasting immunity.1,7

 Learn how LoadingPfizerPro Customer Service

Speak to a member of our customer service team for support and information.

 Contact us Loading View Summary of Product Characteristics  Apexxnar® Loading Prevenar 13® Loading

Legal Category: S1A
Further information is available upon request

PP-PNR-IRL-0014 Date of Preparation: August 2022

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.

 

Copyright © 2023 Pfizer Limited. All rights reserved.

PP-UNP-IRL-0176. January 2023
For Healthcare Professionals in the Republic of Ireland *

The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.

I confirm that I am a healthcare professional resident in the Republic of Ireland.*

I accept and agree to the terms of use.*

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.

PP-UNP-IRL-0176. January 2023

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.
PP-UNP-IRL-0176. January 2023